Moreover, long-term therapy with pegvisomant, a GH receptor antagonist, normalizes IGF-I, improves acromegalic cardiomyopathy by reducing myocardial hypertrophy, and enhances diastolic and systolic function, resulting in the partial or complete reversal of heart failure [79]. Here, IGF1 is linked to cardiac hypertrophy.